We are delighted to announce that Dr. Kathryn (Kate) Owen has joined tranScrip as Executive Medical Director in our Early Development Group.

Kate brings with her 24 years of extensive experience as a consultant Pharmaceutical Physician, with a specialised focus in oncology and haemato-oncology. She has an exceptional track record in early clinical development, guiding projects from candidate drug selection through to phase IIb trials.

Throughout her 16-year career at AstraZeneca, Kate held various pivotal roles in early development, before transitioning into consultancy. For the past 8 years, she has worked as an independent consultant for biotech companies across Europe and the USA.

Linda Summerton, Chief Scientific Officer and Head of Oncology at tranScrip, commented: “We are delighted to welcome Kate to the team. Her deep expertise in oncology and early-stage drug development will be invaluable as we continue to push the boundaries in clinical research and innovation. Kate’s experience in leading complex drug development projects aligns perfectly with tranScrip’s mission to enable our clients to maximise the value of their products for the benefit of patients worldwide.”

Kate commented, “I am delighted to join such an expert and experienced team at tranScrip, as we work together to bring new therapies to patients in this exciting era of pharmaceutical discovery and development.”

Kate holds Specialist Registration in Pharmaceutical Medicine with the General Medical Council (GMC) and has contributed significantly to the pharmaceutical community. Her accomplishments include serving as an Officer of the Board of Examiners for the Diploma in Pharmaceutical Medicine (Dip.Pharm.Med.), earning an MSc in Advanced Therapy Medicinal Products (ATMP), and regularly lecturing on early drug development. She is also a speaker and facilitator for the Dip.Pharm.Med. course.

In her new role at tranScrip, Kate will play a key role as part of our Oncology Therapy Area team.

For more information about tranScrip and its services, please visit www.transcrip-group.com/